These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33427690)

  • 41. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
    Ligero M; Garcia-Ruiz A; Viaplana C; Villacampa G; Raciti MV; Landa J; Matos I; Martin-Liberal J; Ochoa-de-Olza M; Hierro C; Mateo J; Gonzalez M; Morales-Barrera R; Suarez C; Rodon J; Elez E; Braña I; Muñoz-Couselo E; Oaknin A; Fasani R; Nuciforo P; Gil D; Rubio-Perez C; Seoane J; Felip E; Escobar M; Tabernero J; Carles J; Dienstmann R; Garralda E; Perez-Lopez R
    Radiology; 2021 Apr; 299(1):109-119. PubMed ID: 33497314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
    Liu X; Bao X; Hu M; Chang H; Jiao M; Cheng J; Xie L; Huang Q; Li F; Li CY
    Nature; 2020 Dec; 588(7839):693-698. PubMed ID: 33177715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory (FoxP3
    Koh J; Hur JY; Lee KY; Kim MS; Heo JY; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Sci Rep; 2020 Nov; 10(1):18994. PubMed ID: 33149213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.
    Kotraiah V; Phares TW; Browne CD; Pannucci J; Mansour M; Noe AR; Tucker KD; Christen JM; Reed C; MacKay A; Weir GM; Rajagopalan R; Stanford MM; Chung CS; Ayala A; Huang J; Tsuji M; Gutierrez GM
    Front Immunol; 2020; 11():264. PubMed ID: 32210956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Ressler JM; Tomasich E; Hatziioannou T; Ringl H; Heller G; Silmbrod R; Gottmann L; Starzer AM; Zila N; Tschandl P; Hoeller C; Preusser M; Berghoff AS
    Target Oncol; 2024 Mar; 19(2):263-275. PubMed ID: 38401029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atypical patterns of response and progression in the era of immunotherapy combinations.
    Ferrara R; Matos I
    Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 57. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.
    Li C; Phoon YP; Karlinsey K; Tian YF; Thapaliya S; Thongkum A; Qu L; Matz AJ; Cameron M; Cameron C; Menoret A; Funchain P; Song JM; Diaz-Montero CM; Tamilselvan B; Golden JB; Cartwright M; Rodriguez A; Bonin C; Vella A; Zhou B; Gastman BR
    J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34807232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers.
    Li Y; Wang J; Wu L; Li X; Zhang X; Zhang G; Xu S; Sun S; Jiao S
    Front Immunol; 2021; 12():649343. PubMed ID: 34163469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.